1207623-97-9

Usage

Uses

Used in Chemical Research:
5-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is used as a reagent in chemical research for its unique structure and properties. Its potential applications in chemical synthesis and drug discovery processes make it a valuable compound for further studies and exploration.
Used in Drug Discovery:
5-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is used as a potential candidate in drug discovery due to its specific structure and properties. Further research is needed to fully understand its potential applications and effectiveness in this field.
Used in Chemical Synthesis:
5-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is used as a component in chemical synthesis processes, where its unique structure and properties can contribute to the development of new compounds and materials. Its versatility in synthesis makes it an important compound for researchers in the field.

Upstream product

• 183208-34-6 5-bromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 73183-34-3 bis(pinacol)diborane 
• 183208-32-4 3,3,5-Tribromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 271-63-6 7-Azaindole 

Downstream Products

• 1613638-68-8 5-[5-((R)-2-hydroxy-1-phenylethylamino)pyridin-3-yl]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one 

Relevant academic research and scientific papers

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER

The invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.

IMIDAZOPYRIDIN-2-ONE DERIVATIVES

A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer